Qiagen N.V. (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages

Qiagen N.V. (NYSE:QGEN) has been given an average rating of “Hold” by the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $43.51.

Several research firms have recently weighed in on QGEN. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 target price on shares of Qiagen in a report on Thursday, August 6th. UBS Group assumed coverage on Qiagen in a report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 price target for the company. JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Berenberg Bank set a $45.50 price target on Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a report on Friday, September 11th.

Qiagen Stock Down 1.3%

Shares of NYSE QGEN opened at $43.82 on Friday. The business has a 50-day moving average of $43.02 and a two-hundred day moving average of $39.92. The company has a market capitalization of $9.03 billion, a price-to-earnings ratio of 22.45, a price-to-earnings-growth ratio of 4.42 and a beta of 0.63. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period in the prior year, the company posted $0.60 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts forecast that Qiagen will post 2.43 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Large investors have recently modified their holdings of the business. Deutsche Bank AG boosted its stake in shares of Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after acquiring an additional 697,342 shares during the last quarter. Amundi grew its stake in shares of Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after buying an additional 524,959 shares during the period. Norges Bank purchased a new stake in Qiagen during the fourth quarter valued at about $166,500,000. Capital International Investors raised its holdings in shares of Qiagen by 11.4% in the 4th quarter. Capital International Investors now owns 2,587,505 shares of the company’s stock worth $116,361,000 after purchasing an additional 264,412 shares during the period. Finally, State Street Corp lifted its stake in shares of Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after purchasing an additional 93,575 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.